Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC

Bibliography

• Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985;35(2):219-26
   PubMed Web of Science ®Google Scholar
• Johnson JD, Young B. Demographics of cerebral metastasis. Neurosurg Clin N Arn 1996;7:337-44
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494-500
   PubMed Web of Science ®Google Scholar
• Legha SS. Treatment of brain metastases from melanoma. J Clin Oncol 2005;23:3155-6
   PubMed Web of Science ®Google Scholar
• Kienast Y, Winkler F. Therapy and prophylaxis of brain metastases. Expert Rev Anticancer Ther 2010;10(11):1763-77
   PubMed Web of Science ®Google Scholar
• Posner JB. Management of central nervous system metastasis. Semin Oncol 1977;4:81-91
   PubMed Web of Science ®Google Scholar
• Addeo R, Cimmino G, Prete SD. Chemotherapy for brain metastasis and quality of life in handbook of disease burdens and quality of life measures. Springer 2010;162:2781-96
   Google Scholar
• NCCN Central Nervous System Cancer Version 2. 2012. Available from: http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf [Accessed 13 August 2012]
   Google Scholar
• Chao JH, Phillips R, Nickson JJ. Roentgen ray therapy for cerebral metastases. Cancer 1954;7:682-9
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Neurooncology 2010;96(1):17-32
   Web of Science ®Google Scholar
• Taimur S, Edelman MJ. Treatment options for brain metastases in patients with non-small cell lung cancer. Curr Treat Options Oncol 4:89-95.2003
   PubMedGoogle Scholar
• Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12(7):884-98
   PubMed Web of Science ®Google Scholar
• Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin N Am 2003;21:1-23
   PubMed Web of Science ®Google Scholar
• Gerstner ER, Fine RL. Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007;25(16):2306-12
   PubMed Web of Science ®Google Scholar
• De Rossi A, Rossi L, Laudisi A, et al. Focus on fotemustine. J Exp Clin Cancer Res 2006;25(4):461-8
   PubMed Web of Science ®Google Scholar
• Silvani A, Gaviani P, Lamperti E, et al. Lecture: fotemustine in brain tumors. Neurol Sci 2011;32(Suppl 2):S255-7
   PubMed Web of Science ®Google Scholar
• Kyritsis AP, Levin VA. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 2011;67(5):971-83
   PubMed Web of Science ®Google Scholar
• Meulemans A, Giroux B, Hannoun P, et al. Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies. Chemotherapy 1991;37(2):86-92
   PubMed Web of Science ®Google Scholar
• Hayes MT, Bartley J, Parsons PG, et al. Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity. Biochemistry 1997;36(35):10646-54
   PubMed Web of Science ®Google Scholar
• Passagne I, Evrard A, Winum JY, et al. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. J Pharmacol Exp Ther 2003;307(2):816-23
   PubMed Web of Science ®Google Scholar
• Lokiec F, Beerblock K, Deloffre P, et al. Study of the clinical pharmacokinetics of fotemustine in various tumor indications. Bull Cancer 1989;76(10):1063-9
   PubMedGoogle Scholar
• Filippeschi S, Colombo T, Bassani D, et al. Antitumor activity of the novel nitrosourea S10036 in rodent tumors. Anticancer Res 1988;8(6):1351-4
   PubMed Web of Science ®Google Scholar
• Iliadis A, Launay-Iliadis MC, Lucas C, et al. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study. Eur J Cancer 1996;32A(3):455-60
   PubMed Web of Science ®Google Scholar
• Ings RM, Gray AJ, Taylor AR, et al. Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. Eur J Cancer 1990;26(7):838-42
   PubMed Web of Science ®Google Scholar
• Rivière A, Le Cesne A, Berille J, et al. Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: preliminary report of a French multicentre phase II trial. Eur J Cancer 1994;30A(5):587-90
   PubMed Web of Science ®Google Scholar
• Rigal-huguet F, Gaspard MH, Attal M, et al. Clinical pharmacokinetics of fotemustine with assessment of passage across the blood–brain barrier. Bull Cancer 1990;21:775-91
   Google Scholar
• Meulemans A, Giroux B, Hannoun P, et al. Permeability of two nitrosoureas, carmustine and fotemustine in rat cortex. Chemotherapy 1989;35(5):313-19
   PubMed Web of Science ®Google Scholar
• Fischel JL, Formento P, Etienne MC, et al. In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother Pharmacol 1990;25(5):337-41
   PubMed Web of Science ®Google Scholar
• Khayat D, Lokiec F, Bizzari JP, et al. Phase I clinical study of the new amino acid linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res 1987;47(24 Pt 1):6782-5
   PubMed Web of Science ®Google Scholar
• Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990;66:1873-8
   PubMed Web of Science ®Google Scholar
• Jacquillat C, Khayat D, Banzet P, et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990;25(4):263-6
   PubMed Web of Science ®Google Scholar
• Merimsky O, Inbar M, Gerard B, Chaitchik S. Fotemustine - an advance in the treatment of metastatic malignant melanoma. Melanoma Res 1992;2(5-6):401-6
   PubMed Web of Science ®Google Scholar
• Chang J, Atkinson H, A'Hern R, et al. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur J Cancer 1994;30A(14):2093-5
   PubMed Web of Science ®Google Scholar
• Falkson CI, Falkson G, Falkson HC. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest New Drugs 1994;12(3):251-4
   PubMed Web of Science ®Google Scholar
• Kleeberg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 1995;5(3):195-200
   PubMed Web of Science ®Google Scholar
• Calabresi F, Aapro M, Becquart D, et al. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 1991;2:377-8
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Wenzel E, Brassow FW, et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991;29:85-7
   PubMed Web of Science ®Google Scholar
• Ristić-Fira A, Korićanac L, Žakula J, et al. Proton inactivation of melanoma cells enhanced by fotemustine. Radiat Prot Dosimetry 2011;143(2-4):503-7
   PubMed Web of Science ®Google Scholar
• Bröcker EB, Bohndorf W, Kämpgen E, et al. Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study. Melanoma Res 1996;6(5):399-401
   PubMed Web of Science ®Google Scholar
• Ridolfi L, Fiorentini G, Guida M, et al. Italian Melanoma Intergroup. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. Melanoma Res 2009;19(2):100-5
   PubMed Web of Science ®Google Scholar
• Avril MF, Bonneterre J, Cupissol D, et al. Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 1992;28A(11):1807-11
   PubMed Web of Science ®Google Scholar
• Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25
   PubMed Web of Science ®Google Scholar
• Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003;13(1):97-103
   PubMed Web of Science ®Google Scholar
• Wu PF, Kuo KT, Kuo LT, et al. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer 2010;68(3):484-90
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Zabbe C, Gouva S, et al. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma. Eur J Cancer Clin Oncol 1989;25(11):1651-2
   PubMedGoogle Scholar
• Le Cesne A, Chabot G, Bérille J, et al. Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer. Lung Cancer 1995;13(1):69-78
   PubMed Web of Science ®Google Scholar
• Rudd R, Allen R, Berille J, et al. Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer. Cancer Chemother Pharmacol 1994;34(5):444-6
   PubMed Web of Science ®Google Scholar
• Pujol JL, Monnier A, Berille J, et al. Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. Br J Cancer 1994;69(6):1136-40
   PubMed Web of Science ®Google Scholar
• Cotto C, Berille J, Souquet PJ, et al. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer 1996;32A(1):69-71
   PubMed Web of Science ®Google Scholar
• Galetta D, Gebbia V, Silvestris N, et al. Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). Lung Cancer 2011;72(1):59-63
   PubMed Web of Science ®Google Scholar
• Khayat D, Giroux B, Berille J, et al. Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest 1994;12(4):414-20
   PubMed Web of Science ®Google Scholar
• Mohr P, Makki A, Breitbart E, Schadendorf D. Combined treatment of stage IV melanoma patients with amifostine and fotemustine - a pilot study. Melanoma Res 1998;8:166-9
   PubMed Web of Science ®Google Scholar
• Raymond E, Haon C, Boaziz C, Coste M. Logistic regression model of fotemustine toxicity combining independent phase II studies. Cancer 1996;78:1980-7
   PubMed Web of Science ®Google Scholar
• Stevens MFG, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbomoyl-3-methyl-imidazo[5,1-d]- 1,2,3,5-tetrazin- 4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative dacarbazine. Cancer Res 1987;47:5846-52
   PubMed Web of Science ®Google Scholar
• Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Can Res 2000;6(7):2585-97
   PubMed Web of Science ®Google Scholar
• Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 2009;8(4):493-9
   PubMed Web of Science ®Google Scholar
• Quirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007;12(9):1114-23
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22(11):2101-7
   PubMed Web of Science ®Google Scholar
• Tas F, Camlica H, Topuz E. Temozolomide in combination with fotemustine in patients with metastatic melanoma. Cancer Chemother Pharmacol 2008;62(2):293-8
   PubMed Web of Science ®Google Scholar
• Soffietti R, Trevisan E, Rudà R. Targeted therapy in brain metastasis. Curr Opin Oncol 2012;24(6):679-86
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7(2):95-106
   PubMed Web of Science ®Google Scholar
• Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13(5):459-65
   PubMed Web of Science ®Google Scholar
• Kleisbauer JP, Guerin JC, Arnaud A, et al. Chemotherapy with high-dose cisplatin in brain metastasis of lung cancers. Bull Cancer 1990;77:661-5; French
   PubMed Web of Science ®Google Scholar
• Cortes J, Rodriguez J, Aramendia JM, et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 2003;64:28-35
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;12:249-54
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Ardizzoni A, Postmus PE, et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003;39:1271-6
   PubMed Web of Science ®Google Scholar
• Giorgio CG, Giuffrida D, Pappalardo A, et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 2005;50:247-54
   PubMed Web of Science ®Google Scholar
• Cortot AB, Geriniere L, Robinet G, et al. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 2006;17(9):1412-17
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M. Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opin Investig Drugs 2011;20(7):881-95
   PubMed Web of Science ®Google Scholar
• Antonadou D, Paraskevaidis M, Sarris M, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002;20:3644-50
   PubMed Web of Science ®Google Scholar
• Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005;61:185-91
   PubMed Web of Science ®Google Scholar
• Kouvaris JR, Miliadou A, Kouloulias VE, et al. Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie 2007;30(7):361-6
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Faiola V, et al. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer 2007;7:18
   PubMed Web of Science ®Google Scholar
• Chua D, Krzakowski M, Chouaid C, et al. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer 2010;11(3):176-81
   PubMed Web of Science ®Google Scholar
• Addeo R, De Rosa C, Faiola V, et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non small cell lung cancer and breast cancer patients with brain metastases. Cancer 2008;113(9):2524-31
   PubMed Web of Science ®Google Scholar
• Shimato S, Mitsudomi T, Kosaka T, et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neurooncology 2006;8:137-44
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004;15:1042-7
   PubMed Web of Science ®Google Scholar
• De Braganca KC, Janjigian YY, Azzoli CG, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010;100(3):443-7
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012;13(9):879-86
   PubMed Web of Science ®Google Scholar
• Del Vecchio M, Mortarini R, Canova S, et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010;16(23):5862-72
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, De Santi MS, et al. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol 2011;102(3):417-24
   PubMed Web of Science ®Google Scholar